2 drugs the first review of "Omeprazole intestinal tablets" into the collection.

On July 8, the official website of the State Drug Administration showed that three drugs passed the consistency evaluation, of which Shandong New Era Pharmaceuticals "Omeprazole intestinal tablets" (10mg) and China Resources Zizhu Pharmaceuticals" miso prostol tablets (200 sg) were the first to pass the consistency evaluation.
omeprazole is a proton pump inhibitor and is clinically used in the treatment of gastric, duodenal ulcers, reflux esophagitis, and Zhuo-Ai syndrome.
at present, there are a variety of approved omeprazole preparations, including injections, ordinary capsules, intestinal capsules, intestinal tablets, etc. , according to Insight database statistics, the current variety only omeprazole intestinal capsules have 4 enterprises through consistency evaluation.
in addition, it is worth noting that in the informal version of the third batch of collection list, there are omeprazole oral frequently released dosage forms, in accordance with the national health insurance catalog of the sample part of the dosage form classification shows that intestinal lysis capsules, intestinal tablets are combined into oral changas.
currently, there are 5 enterprises that have passed consistency evaluation of omeprazole oral oftenrelease sedatives.
public data show that in 2019, the sales of omeprazole oral frequently released agent form of omeprazole in public medical institutions in China will be about 2.5 billion yuan, and sample hospital data show that The omeprazole intestinal capsules of Changzhou Four Drug Pharmaceuticals account for nearly 65% of the market share, followed by Cornbey Pharmaceuticals for about 28%. according to the
Insight database, Yuekang Pharmaceuticals, Zhejiang Jinhuakang Enbei, Yantai LuYin Pharmaceuticals submitted additional applications for consistency evaluation, of which Cornbey as early as 2019 showed the issuance of approvals, the specific review conclusions are not known.
.